According to American Diabetes Association 2022 recommendations, GLP-1 RAs with or without metformin is an acceptable starting treatment for individuals with T2DM who have with or are at high risk for atherosclerotic cardiovascular disease, heart failure, and/or chronic kidney disease (American Diabetes, 2022). This evidence concerns the gene GCG and type 2 diabetes mellitus.